148 related articles for article (PubMed ID: 25735654)
1. Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma.
Raju SC; Hauff SJ; Lemieux AJ; Orosco RK; Gross AM; Nguyen LT; Savariar E; Moss W; Whitney M; Cohen EE; Lippman SM; Tsien RY; Ideker T; Advani SJ; Nguyen QT
Oral Oncol; 2015 May; 51(5):470-5. PubMed ID: 25735654
[TBL] [Abstract][Full Text] [Related]
2. Matrix-metalloproteinases in head and neck carcinoma-cancer genome atlas analysis and fluorescence imaging in mice.
Hauff SJ; Raju SC; Orosco RK; Gross AM; Diaz-Perez JA; Savariar E; Nashi N; Hasselman J; Whitney M; Myers JN; Lippman SM; Tsien RY; Ideker T; Nguyen QT
Otolaryngol Head Neck Surg; 2014 Oct; 151(4):612-8. PubMed ID: 25091190
[TBL] [Abstract][Full Text] [Related]
3. Low expression of fragile histidine triad gene correlates with high proliferation in head and neck squamous cell carcinoma.
Mineta H; Miura K; Takebayashi S; Misawa K; Ueda Y; Suzuki I; Ito M; Wennerberg J
Oral Oncol; 2003 Jan; 39(1):56-63. PubMed ID: 12457722
[TBL] [Abstract][Full Text] [Related]
4. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.
Gross AM; Orosco RK; Shen JP; Egloff AM; Carter H; Hofree M; Choueiri M; Coffey CS; Lippman SM; Hayes DN; Cohen EE; Grandis JR; Nguyen QT; Ideker T
Nat Genet; 2014 Sep; 46(9):939-43. PubMed ID: 25086664
[TBL] [Abstract][Full Text] [Related]
5. Aberration of FHIT gene is associated with increased tumor proliferation and decreased apoptosis-clinical evidence in lung and head and neck carcinomas.
Pavelić K; Krizanac S; Cacev T; Hadzija MP; Radosević S; Crnić I; Levanat S; Kapitanović S
Mol Med; 2001 Jul; 7(7):442-53. PubMed ID: 11683369
[TBL] [Abstract][Full Text] [Related]
6. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck.
Kisielewski AE; Xiao GH; Liu SC; Klein-Szanto AJ; Novara M; Sina J; Bleicher K; Yeung RS; Goodrow TL
Oncogene; 1998 Jul; 17(1):83-91. PubMed ID: 9671317
[TBL] [Abstract][Full Text] [Related]
8. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines.
Mao L; Fan YH; Lotan R; Hong WK
Cancer Res; 1996 Nov; 56(22):5128-31. PubMed ID: 8912845
[TBL] [Abstract][Full Text] [Related]
9. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.
Skinner HD; Sandulache VC; Ow TJ; Meyn RE; Yordy JS; Beadle BM; Fitzgerald AL; Giri U; Ang KK; Myers JN
Clin Cancer Res; 2012 Jan; 18(1):290-300. PubMed ID: 22090360
[TBL] [Abstract][Full Text] [Related]
10. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity.
Rieckmann T; Tribius S; Grob TJ; Meyer F; Busch CJ; Petersen C; Dikomey E; Kriegs M
Radiother Oncol; 2013 May; 107(2):242-6. PubMed ID: 23602369
[TBL] [Abstract][Full Text] [Related]
11. Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication.
Tai SK; Lee JI; Ang KK; El-Naggar AK; Hassan KA; Liu D; Lee JJ; Ren H; Hong WK; Mao L
Clin Cancer Res; 2004 Aug; 10(16):5554-7. PubMed ID: 15328196
[TBL] [Abstract][Full Text] [Related]
12. Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival.
Helland A; Kraggerud SM; Kristensen GB; Holm R; Abeler VM; Huebner K; Borresen-Dale AL; Lothe RA
Int J Cancer; 2000 Oct; 88(2):217-22. PubMed ID: 11004671
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.
Alsner J; Sørensen SB; Overgaard J
Radiother Oncol; 2001 May; 59(2):179-85. PubMed ID: 11325447
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck.
González MV; Pello MF; Ablanedo P; Suárez C; Alvarez V; Coto E
J Clin Pathol; 1998 Jul; 51(7):520-4. PubMed ID: 9797729
[TBL] [Abstract][Full Text] [Related]
15. Fhit expression is absent or reduced in a subset of primary head and neck cancer.
Götte K; Hadaczek P; Coy JF; Wirtz HW; Riedel F; Neubauer J; Hörmann K
Anticancer Res; 2000; 20(2A):1057-60. PubMed ID: 10810397
[TBL] [Abstract][Full Text] [Related]
16. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status.
Sandulache VC; Skinner HD; Ow TJ; Zhang A; Xia X; Luchak JM; Wong LJ; Pickering CR; Zhou G; Myers JN
Cancer; 2012 Feb; 118(3):711-21. PubMed ID: 21720999
[TBL] [Abstract][Full Text] [Related]
17. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck.
Franchi A; Santucci M; Masini E; Sardi I; Paglierani M; Gallo O
Cancer; 2002 Nov; 95(9):1902-10. PubMed ID: 12404284
[TBL] [Abstract][Full Text] [Related]
18. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.
Peltonen JK; Vähäkangas KH; Helppi HM; Bloigu R; Pääkkö P; Turpeenniemi-Hujanen T
Head Neck Oncol; 2011 Apr; 3():20. PubMed ID: 21513535
[TBL] [Abstract][Full Text] [Related]
19. FHIT gene alterations in head and neck squamous cell carcinomas.
Virgilio L; Shuster M; Gollin SM; Veronese ML; Ohta M; Huebner K; Croce CM
Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9770-5. PubMed ID: 8790406
[TBL] [Abstract][Full Text] [Related]
20. Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.
Sano D; Xie TX; Ow TJ; Zhao M; Pickering CR; Zhou G; Sandulache VC; Wheeler DA; Gibbs RA; Caulin C; Myers JN
Clin Cancer Res; 2011 Nov; 17(21):6658-70. PubMed ID: 21903770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
